Management of T2D in older adults is complex due to the clinical, cognitive, and functional heterogeneity of this population, and, although some older adults with T2D may achieve disease control with oral glucose-lowering agents, many will require insulin as the disease progresses
Full text: Tsermpini, E
In December 2025, the Food and Drug Administration (FDA) approved an oral pill form of Wegovy for weight loss, and in April 2026 approved the once-daily oral GLP-1 drug Foundayo (orforglipron) also for weight loss
Heres how: 1
Invyncible is a telemedicine provider network, not a pharmacy
For example, its possible that: people who used GLP-1 could be more informed about treatment options and more motivated to manage their own health people who used GLP-1 may have received it because their health-care team were motivated to offer the latest treatment options, which could lead to better care in other areas that impact the risk of various health outcomes people who used GLP-1 may have been able to do so because they lived in metropolitan centres and could afford the medication, as well as other health-promoting services and products, such as gyms, mental health care, or healthy food delivery services